NSEGeneral Updates16 Oct 2026 · 16 Oct 2026, 04:58 pm

General Updates

Zydus Lifesciences Limited · ZYDUSLIFE

✦ AI SummaryESG

Zydus Lifesciences Limited has informed the Exchange about General Updates ESG Rating. The company has received an overall ESG rating of 71 from NSE Sustainability Ratings and Analytics Limited, a subsidiary of NSE Indices Limited, for the financial year 2026, which is categorized as 'leader'. The report was received via email on October 15, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk5/10
Liquidity Impact8/10
Market Sentiment6/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Zydus Lifesciences Limited has informed the Exchange about General Updates ESG Rating

Attachments (1)

📄

Cadilahc_16102026165747_SEIntimationESGRating16102026.pdf

pdf

Download →
View document text
October 16, 2026 BSE Limited Code: 532321 1st Floor, P J Towers, Dalal Street, Mumbai-400001 Na(cid:415)onal Stock Exchange of India Limited Code: Zyduslife Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051 Sub.: ESG Ra(cid:415)ng Ref.: Disclosure under regula(cid:415)on 30 read with Schedule III of SEBI (Lis(cid:415)ng Obliga(cid:415)ons and Disclosure Requirements) Regula(cid:415)ons, 2015 (“the Lis(cid:415)ng Regula(cid:415)ons”) and SEBI Master Circular dated January 30, 2026 (“the SEBI Master Circular”) Dear Sir / Madam, This is to inform that NSE Sustainability Ra(cid:415)ngs and Analy(cid:415)cs Limited (“NSRAL”), a subsidiary of NSE Indices Limited and a group company of Na(cid:415)onal Stock Exchange of India Limited, a SEBI registered ESG Ra(cid:415)ng Provider, has assigned overall ESG ra(cid:415)ng of 71 to the Company for the financial year 2026, which is covered under category of ‘leader’. The report was received by way of an email on October 15, 2026, at 17.29 hours. Please note that this is an unsolicited ra(cid:415)ng and NSRAL has independently prepared the report based on data pertaining to the Company available in public domain. This disclosure is made in compliance with the provisions of regula(cid:415)on 30 of the Lis(cid:415)ng Regula(cid:415)ons read with the SEBI Circular. Thanking you, Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063